Literature DB >> 16985658

Chemoprevention strategies in the prostate: an overview.

Gary J Kelloff, Howard R Higley, Michael K Brawer, M Scott Lucia, Caroline C Sigman, E David Crawford.   

Abstract

Chemoprevention is the administration of agents (drugs, biologics, and nutrients) to prevent induction, inhibit, or delay the progression of cancers. Prostate cancer is an important target for chemoprevention because of its long latency and high prevalence. The development of rational chemopreventive strategies requires knowledge of the mechanisms of prostate carcinogenesis and identification of agents that interfere with these mechanisms. Because of the long time period for prostate carcinogenesis and the large size of the cohort required for an evaluable study, identification and characterization of early intermediate biomarkers and their validation as surrogate endpoints for cancer incidence are essential for chemopreventive agent development. Finally, suitable populations with appropriate risk factors, including the presence of premalignant lesions and genetic predispositions, need to be well characterized for future chemopreventive interventions.

Entities:  

Year:  2002        PMID: 16985658      PMCID: PMC1475973     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  69 in total

Review 1.  New agents for chemoprevention of prostate cancer.

Authors:  M B Sporn
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

2.  Cancer statistics, 1999.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1999 Jan-Feb       Impact factor: 508.702

3.  A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells.

Authors:  W Zhu; A Smith; C Y Young
Journal:  Endocrinology       Date:  1999-11       Impact factor: 4.736

Review 4.  Lipoxygenase inhibitors as potential cancer chemopreventives.

Authors:  V E Steele; C A Holmes; E T Hawk; L Kopelovich; R A Lubet; J A Crowell; C C Sigman; G J Kelloff
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-05       Impact factor: 4.254

Review 5.  Prostate cancer chemoprevention by green tea.

Authors:  S Gupta; N Ahmad; H Mukhtar
Journal:  Semin Urol Oncol       Date:  1999-05

6.  Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder.

Authors:  K V Rao; C J Detrisac; V E Steele; E T Hawk; G J Kelloff; D L McCormick
Journal:  Carcinogenesis       Date:  1996-07       Impact factor: 4.944

7.  Intake of carotenoids and retinol in relation to risk of prostate cancer.

Authors:  E Giovannucci; A Ascherio; E B Rimm; M J Stampfer; G A Colditz; W C Willett
Journal:  J Natl Cancer Inst       Date:  1995-12-06       Impact factor: 13.506

8.  Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide.

Authors:  M Pollard; P H Luckert; M B Sporn
Journal:  Cancer Res       Date:  1991-07-01       Impact factor: 12.701

9.  Subversion of immune system by tumor cells and role of prostaglandins.

Authors:  O J Plescia; A H Smith; K Grinwich
Journal:  Proc Natl Acad Sci U S A       Date:  1975-05       Impact factor: 11.205

10.  Non-steroidal anti-inflammatory drugs and prostate cancer progression.

Authors:  A E Norrish; R T Jackson; C U McRae
Journal:  Int J Cancer       Date:  1998-08-12       Impact factor: 7.396

View more
  3 in total

1.  Chemoprevention and prostate cancer.

Authors:  Masood A Khan; Alan W Partin
Journal:  Rev Urol       Date:  2003

2.  Assessment of information to substantiate a health claim on the prevention of prostate cancer by lignans.

Authors:  Niina M Saarinen; Juhani Tuominen; Liisa Pylkkänen; Risto Santti
Journal:  Nutrients       Date:  2010-01-28       Impact factor: 5.717

3.  A phase II randomized clinical trial using aglycone isoflavones to treat patients with localized prostate cancer in the pre-surgical period prior to radical prostatectomy.

Authors:  Nagi B Kumar; Julio Pow-Sang; Philippe Spiess; Shohreh Dickinson; Michael J Schell
Journal:  Oncotarget       Date:  2020-04-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.